title: Pazopanib  for the treatment of breast cancer.
abstract: BACKGROUND
  Several clinical trials have shown clinical benefit of angiogenesis inhibitors in the treatment of solid tumors. Pazopanib is a multitargeted tyrosine kinase inhibitor that is currently approved for the treatment of patients with advanced renal cell carcinoma (RCC).
  
  
  METHODS
  In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. Preclinical data show the anti-tumor activity of pazopanib in animal models. Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway.
  
  
  CONCLUSIONS
  The development of biomarkers predictive of response and toxicity to angiogenesis inhibitors remains a challenging endeavor and is necessary to help guide treatment decision.
authors.affiliation: National Cancer Institute, 10 Center Drive, 12N226, Bethesda, MD, USA.
authors.forename: Laleh
authors.initials: L
authors.lastname: Amiri-Kordestani
authors.forename: Antoinette R
authors.initials: AR
authors.lastname: Tan
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Swain
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D007191:Indazoles; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D011505:Protein-Tyrosine Kinases